Launch PEMFEXY

Deadline passed; outcome being checked

What the company said

“Q1 2022 launch”

SourceEagle Pharmaceuticals, Inc. Form 8-K press release, 2021-01-13
FilingSEC filing index
Deadline as statedQ1 2022
Deadline used31 Mar 2022, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-C827871-021972
Cite as https://keptindex.org/c/KI-C-2021-C827871-021972/ — this address never changes.

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Version 1 · original · stated 13 Jan 2021

Deadline 31 Mar 2022 (“Q1 2022”)
Version 2 · stated 2 Mar 2021

Deadline 28 Feb 2022 (“in February 2022”)

“we have our exclusive Pemfexy launch in February 2022”
Source for this version

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Eagle Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.